GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas

Condition:   Glioma, Malignant Interventions:   Biological: AdV-tk;   Drug: Valacyclovir;   Radiation: Radiation;   Drug: Temozolomide;   Biological: Nivolumab;   Other: Laboratory Biomarker Analysis Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Advantagene, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials